Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, focusing on innovation and growth opportunities in various segments [4]. Core Insights - The pharmaceutical sector is experiencing a comprehensive recovery, with a focus on innovative drug development, particularly in oncology, autoimmune diseases, GLP-1, stem cell therapy, and gene therapy [1][2]. - The report highlights the importance of domestic innovation in pharmaceuticals, with significant attention on the upcoming AACR and ASCO conferences, where numerous Chinese companies are expected to present their research [2][13]. - The report emphasizes the potential for growth in the CXO sector due to recovering domestic demand and stable overseas demand, suggesting a valuation recovery for leading companies [8]. - The report identifies key companies to watch, including 恒瑞医药, 百济神州, and others across various segments such as innovative drugs, medical devices, and IVD [3]. Summary by Sections Innovative Drugs - The report notes the approval of 康方依沃西单抗 for first-line treatment of PD-L1 positive NSCLC, showing a 22.3% reduction in mortality risk [2]. - It highlights the upcoming AACR conference with over 120 Chinese pharmaceutical companies presenting nearly 300 new drug research results [13]. CXO Sector - The CXO sector is expected to benefit from supportive policies and a reduction in geopolitical risks, leading to a potential valuation uplift [8]. Traditional Chinese Medicine - The report suggests monitoring companies related to pediatric medications, such as 济川药业 and 葵花药业, due to their relevance to fertility subsidies [2]. Blood Products - The report emphasizes the growth potential in the immunoglobulin market over the next 3-5 years, driven by increased demand and pricing improvements [2][25]. Vaccines - The vaccine sector is under pressure, but there are opportunities in HPV vaccines and other high-value products [27]. Upstream Supply Chain - The report recommends focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [30]. IVD Sector - The report indicates that the IVD industry is poised for growth due to the implementation of centralized procurement policies and increasing domestic demand [33]. Medical Devices - The report highlights the potential for growth in the CGM market, particularly with the FDA approval of related products [38]. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [44]. Offline Pharmacies - The report notes that the pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [46]. Raw Materials - The report discusses the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [50]. Innovative Devices - The report emphasizes the potential for AI applications in medical devices, particularly in surgical navigation and pathology screening [53]. Instrumentation - The report anticipates a recovery in the scientific instrumentation sector, driven by increased domestic demand and new product launches [57].

Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, highlighting a recovery and focus on innovation [4]. Core Views - The pharmaceutical sector is experiencing a sustained recovery in fundamentals, supported by favorable policies, with a focus on innovative drug growth, particularly in areas such as oncology, autoimmune diseases, GLP-1, stem cell therapy, and gene therapy [1][2]. - The report emphasizes the importance of domestic pharmaceutical substitution and the growth of medical consumption, especially in aesthetic medicine [1]. Summary by Sections Innovative Drugs - The AACR conference is ongoing, with significant participation from over 120 Chinese pharmaceutical companies presenting nearly 300 new drug research results [11]. - Key approvals include the domestic approval of 康方依沃西单抗 for PD-L1 positive NSCLC and the FDA approval of 派安普利单抗 for nasopharyngeal carcinoma [2][72]. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive policies for innovative drug development and a reduction in geopolitical risks [6]. Traditional Chinese Medicine - The SW secondary index for traditional Chinese medicine has underperformed compared to the broader market, indicating challenges in this segment [19]. Blood Products - The report highlights the increasing demand for immunoglobulin products and the potential for price improvements in the blood products sector, particularly for companies like 天坛生物 and 派林生物 [23]. Vaccines - The vaccine sector is facing challenges due to low birth rates, but there is potential for growth in HPV vaccines and other areas [25]. Upstream Supply Chain - The report suggests focusing on companies with strong brand and operational capabilities in the chemical and biological reagent sectors [28]. IVD (In Vitro Diagnostics) - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic substitution [31]. Medical Devices - The report recommends attention to the CGM market, particularly products from 三诺生物, as they align with the growth of GLP-1 drugs [36]. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [43]. Offline Pharmacies - The offline pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies like 华海药业 and 海正药业 [49]. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [52]. Instrument Equipment - The scientific instrument sector is expected to recover as demand improves, with a focus on companies enhancing their market presence through new product launches [57]. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies like 采纳股份 and 美好医疗 [60].

上述募集资金到位情况已由普华永道中天会计师事务所（特殊普通合伙）审 验，并已于 2018 年 10 月 10 日出具"普华永道中天验字(2018)第 0626 号"《验 资报告》。公司已对募集资金采取了专户存储，相关募集资金已全部存放于募集 资金专户，并且公司及相关子公司与存放募集资金的商业银行、保荐机构签订了 《募集资金三方监管协议》、《募集资金四方监管协议》。 二、募集资金投资项目的基本情况 根据《深圳迈瑞生物医疗电子股份有限公司首次公开发行股票并在创业板上 市招股说明书》及公司召开的第七届董事会第三次会议、第七届董事会第五次会 议、第七届董事会第十次会议、2019 年年度股东大会和 2020 年年度股东大会， 1 核查意见 华泰联合证券有限责任公司 关于深圳迈瑞生物医疗电子股份有限公司 部分募集资金投资项目结项 并将节余募集资金永久补充流动资金的公告 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为深圳迈瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"、"公司"）首次 公开发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保 荐业务管理办法》、《上市公司监管指引第 ...

深圳迈瑞生物医疗电子股份有限公司 2024年度内部控制审计报告 安永华明（2025）专字第70024693_H01号 深圳迈瑞生物医疗电子股份有限公司 深圳迈瑞生物医疗电子股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计 了深圳迈瑞生物医疗电子股份有限公司 2024 年 12 月 31 日的财务报告内部控制的有效 性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是深圳迈瑞生物医疗电子 股份有限公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 按照中国证监会发布《上市公司实施企业内部控制规范体系监管问题解答》（2011 年第 1 期，总第 1 期）的相关豁免规定，深圳迈瑞生物医疗电子股份有限公司未将于 2024 年度并购的子公司深圳惠泰医疗器械股份有限公司及其下属子公司（"惠泰医疗集 团"）的内部控制包括在深圳迈瑞生物医疗电子股份 ...

Group 1: Poly Developments - Poly Developments reported a net profit of 5 billion yuan for 2024, a decrease of 58.6% year-on-year [1] - The company achieved total revenue of 311.67 billion yuan in 2024, down 10% from the previous year [2] - The gross profit margin for settlements was 14%, a decline of 2 percentage points compared to the same period last year [1][2] - The company signed a total area of 17.9661 million square meters, a decrease of 24.7% year-on-year, while sales contracts amounted to 323.029 billion yuan, down 23.5% [2] - The company maintained a cash balance of 134.2 billion yuan at the end of the year, with a net cash flow from operating activities of 6.257 billion yuan [3] Group 2: Mindray Medical - Mindray Medical reported a revenue of 36.726 billion yuan for 2024, an increase of 5.14% year-on-year [5][6] - The net profit attributable to shareholders was 11.668 billion yuan, a slight increase of 0.74% compared to the previous year [5][6] - The company's cash flow from operating activities was not disclosed in the provided data [6] Group 3: Unisplendour - Unisplendour announced plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - The company achieved a revenue of 79.024 billion yuan in 2024, a growth of 2.22% year-on-year [10] - The net profit attributable to shareholders was 1.572 billion yuan, a decrease of 25.23% compared to the previous year [10] Group 4: SF Holding - SF Holding reported a revenue of 69.849 billion yuan for the first quarter, an increase of 6.9% year-on-year [17][18] - The net profit attributable to shareholders was 2.234 billion yuan, reflecting a growth of 16.9% compared to the same period last year [17][18] - The company plans to repurchase shares worth between 500 million and 1 billion yuan [17] Group 5: Qingdao Beer - Qingdao Beer reported a revenue of 10.445 billion yuan for the first quarter, a growth of 2.91% year-on-year [20][21] - The net profit attributable to shareholders was 1.710 billion yuan, an increase of 7.08% compared to the previous year [20][21] Group 6: China State Construction - China State Construction reported a revenue of 555.3 billion yuan for the first quarter, a growth of 1.1% year-on-year [23] - The net profit attributable to shareholders was 15.01 billion yuan, reflecting a growth of 0.6% compared to the same period last year [23] Group 7: WuXi AppTec - WuXi AppTec reported a revenue of 9.655 billion yuan for the first quarter, a growth of 20.96% year-on-year [24] - The net profit attributable to shareholders was 3.672 billion yuan, a significant increase of 89.06% compared to the previous year [24] Group 8: China Nuclear Power - China Nuclear Power reported a revenue of 20.273 billion yuan for the first quarter, a growth of 12.7% year-on-year [25] - The net profit attributable to shareholders was 3.137 billion yuan, reflecting a growth of 2.55% compared to the same period last year [25] Group 9: Haitian Flavoring - Haitian Flavoring reported a revenue of 8.315 billion yuan for the first quarter, a growth of 8.08% year-on-year [26] - The net profit attributable to shareholders was 2.202 billion yuan, an increase of 14.77% compared to the previous year [26] Group 10: Yunnan Baiyao - Yunnan Baiyao reported a revenue of 10.841 billion yuan for the first quarter, a growth of 0.62% year-on-year [27] - The net profit attributable to shareholders was 1.935 billion yuan, reflecting a growth of 13.67% compared to the same period last year [27]

子公司管理制度 第一章 总则 若公司合并报表范围内的子公司属于上市公司的，在不违背该等上市子公 司股票上市地证券监管规则的前提下，其仍应当适用本制度的相关规定和 要求。 第三条 各子公司应遵循本制度, 结合公司的相关内部控制规定, 根据自身经营 特点, 可制定具体的实施细则, 以保证本制度的贯彻和执行。公司各职能 部门应按相关内控制度, 及时对子公司做好服务、指导、监督等工作。 公司亦可结合各子公司的组织架构、内部控制特点，在符合法律法规的前 提下，对组织架构或职能较为简单的子公司采取垂直管理、直接管理等管 理方式，并及时对子公司做好服务、指导、监督等工作。 第四条 公司的子公司同时控股其他公司的, 应参照本制度的要求逐层建立对其 1 第一条 为加强深圳迈瑞生物医疗电子股份有限公司(以下简称"公司")内部控 制, 促进公司规范运作和健康发展, 保护投资者合法权益, 加强对控股 子公司(或称"子公司")的管理控制, 规范控股子公司行为, 保证控股 子公司规范运作和依法经营, 根据《中华人民共和国公司法》《中华人民 共和国证券法》等法律法规和规范性文件, 以及《深圳迈瑞生物医疗电子 股份有限公司章程》(以下简称" ...

信息的保密，一旦出现泄密的情形，公司应当按有关规定及时予以披 露。 第二章 投资者关系工作的内容和方式 深圳迈瑞生物医疗电子股份有限公司 第六条 投资者关系工作中公司与投资者沟通的内容主要包括： 投资者关系管理制度 第一章 总则 1 第一条 为切实加强深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）与投 资者之间的沟通交流，增进投资者对公司的了解和认同，完善公司治理结构， 切实保护投资者特别是社会公众投资者的合法权益，公司根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司投资者关系管理工作指引》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》等法律、法规和规范性文件及《深圳迈瑞生物医疗电子股份有限公司 章程》（以下简称"《公司章程》"），制定本制度。 第二条 投资者关系工作是指公司通过便利股东权利行使、信息披露、互动交流和诉 求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对公司 的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系工作的目的是: (一) 促进公司与投资者之间的良 ...

深圳迈瑞生物医疗电子股份有限公司 董事和高级管理人员所持公司股份及其变动 管理制度 第一章 总 则 第一条 为加强对深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"） 董事和高级管理人员持有或买卖公司股票行为的申报、披露与监督和管理，维护 证券市场秩序，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上市公司股东 减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第10号——股 份变动管理》《深圳证券交易所上市公司自律监管指引第18号——股东及董事、 高级管理人员减持股份》等法律、法规、规范性文件，以及《公司章程》的有关 规定，结合公司的实际情况，特制定本制度。 第二条 公司董事和高级管理人员在买卖公司股票及其衍生品种前，应知悉 并遵守《中华人民共和国公司法》《中华人民共和国证券法》等法律、法规关于 内幕交易、操纵市场、短线交易等禁止行为的规定，不得进行违法违规的交易。 公司董事和高级管理人员等主体对持有股份比例、持有期限、变动方式、变动价 格等作出承诺的，应当 ...

深圳迈瑞生物医疗电子股份有限公司 董事会秘书工作细则 第一章 总 则 董事会秘书为履行职责有权了解公司的财务和经营情况，参加涉及信息披 露的有关会议，查阅涉及信息披露的所有文件，并要求公司有关部门和人 员及时提供相关资料和信息。 第六条 公司董事会秘书应当由公司董事、副总经理、财务负责人或《公司章程》 规定的其他高级管理人员担任。 第三章 主要职责 第七条 董事会秘书的主要职责是： 2 第二章 任职资格 1 第一条 为进一步规范深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"） 法人治理结构，明确董事会秘书的工作职责和程序，充分发挥董事会秘书 的作用，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）和《深圳迈瑞生 物医疗电子股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，制定本工作细则。 第二条 公司设董事会秘书一名，董事会秘书是公司的高级管理人员。董事会秘书 为公司与证券交易所的指定联系人。董事会秘书对董事会负责，承担法律、 法规及《公司章程》所规定的公司高级管理人员的义务，享有相应的工作 职权。 第三条 公司应当为董事会秘书履行职责 ...

深圳迈瑞生物医疗电子股份有限公司 金融衍生品交易管理制度 第一章 总则 第一条 为规范深圳迈瑞生物医疗电子股份有限公司(以下简称"公司")金 融衍生品交易业务，控制金融衍生品交易风险，根据《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券 交易所上市公司自律监管指引第 7 号——交易与关联交易》等法律、法规及《公 司章程》的有关规定，结合公司的实际业务情况，制定本制度。 本制度所称金融衍生品交易，是指远期、期货、掉期（互换）和期权等产品 或者混合上述产品特征的金融工具交易。衍生品的基础资产既可以是证券、指数、 利率、汇率、货币、商品等标的，也可以是上述标的的组合。 第二条 本制度适用于公司及控股子公司的金融衍生品交易。未经公司同意, 公司下属控股子公司不得进行金融衍生品交易业务。 若公司合并报表范围内的子公司属于上市公司的，则该等上市子公司的金融 衍生品交易应当遵守其股票上市地证券监管规则。若该等上市子公司的金融衍生 品交易需履行公司审议或披露程序或可能对公司产生影响的，则该等上市子公司 ...